Bezisterim: Difference between revisions
Content deleted Content added
←Created page with ''''NE3107''' is an analog of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood-brain barrier and does not activate any neurotransmitter receptors.<ref>{{cite journal |last1=Reading |first1=Chris L |last2=Ahlem |first2=Clarence N |last3=Parameswaran |first3=Narayanan |title=Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease tria...' |
(No difference)
|
Revision as of 05:57, 14 December 2023
NE3107 is an analog of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain. The compound crosses the blood-brain barrier and does not activate any neurotransmitter receptors.[1] It has been tested as a treatment for Alzheimer’s disease[2][3][4][5] and traumatic brain injury.[6]
References
 |
- ^ Reading, Chris L; Ahlem, Clarence N; Parameswaran, Narayanan (December 2021). "Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial". Alzheimer's & Dementia. 17 (S9). doi:10.1002/alz.057438.
- ^ Stoiljkovic, Milan; Horvath, Tamas L.; Hajós, Mihály (July 2021). "Therapy for Alzheimer's disease: Missing targets and functional markers?". Ageing Research Reviews. 68: 101318. doi:10.1016/j.arr.2021.101318.
- ^ Balzano, Tiziano; Esteban-García, Noelia; Blesa, Javier (2 January 2023). "Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots". Expert Opinion on Drug Discovery. 18 (1): 13–23. doi:10.1080/17460441.2023.2160440.
- ^ Liu, Ping; Wang, Yunyun; Sun, Yan; Peng, Guoping (April 2022). "Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease". Clinical Interventions in Aging. 17: 665–674. doi:10.2147/CIA.S357558.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ Xi, Yilong; Chen, Yun; Jin, Yi; Han, Guochen; Song, Mingjie; Song, Tingting; Shi, Yang; Tao, Ling; Huang, Zewei; Zhou, Jianping; Ding, Yang; Zhang, Huaqing (May 2022). "Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy". Journal of Controlled Release. 345: 38–61. doi:10.1016/j.jconrel.2022.02.034.
- ^ "U.S. Clinical Trial: Neurological Associates of West Los Angeles Listed a New Clinical Trial to Study Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury." Contify Life Science News, 1 Aug. 2023, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A759542006/HRCA?u=anon~bb46c85&sid=sitemap&xid=0c315c7e. Accessed 14 Dec. 2023.